Oppenheimer: Q2 Earnings Snapshot
The New York-based company said it had earnings of $1.91 per share.
The investment banking and broker-dealer services provider posted revenue of $373.2 million in the period. Its revenue net of interest expense was $373.2 million, which beat Street forecasts.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Is JPMorgan Chase Stock a Buy Right Now?
Key Points JPMorgan Chase's latest financial results came in well ahead of Wall Street estimates. The massive bank is certainly exposed to changing macro forces, and CEO Jamie Dimon is fully aware of near-term risks. Based on two popular valuation metrics, the stock looks expensive today. 10 stocks we like better than JPMorgan Chase › Investors probably don't expect huge gains from businesses that operate in a very mature industry like financial services. But JPMorgan Chase (NYSE: JPM) has shown that it can be a big winner. The massive bank has generated a total return of 252% in the past five years (as of July 28). The company continues to report strong financial results that keep supporting the bullish fever among the investment community. This financial stock trades in record territory. So, is JPMorgan Chase a buy right now? Beating estimates It seems that every single quarter, JPMorgan Chase's latest numbers come in well ahead of Wall Street analyst estimates. This is exactly what happened in Q2, which ended on June 30, with both revenue and diluted earnings per share (EPS) beating expectations handily. During the three-month period, the company reported net revenue of $44.9 billion. The commercial and investment banking segment was the standout performer, with net revenue up 9% year over year. Trading activity and deal-making were both robust. JPMorgan Chase raked in net income of $15 million in Q2. This points to just how profitable the business is, with its superb net profit margin of 33.4% in the latest quarter. This supports management's capital allocation policy, with $3.9 billion paid in dividends and $7.1 billion going to share buybacks in the past three months. Jamie Dimon's cautious outlook The economy appears to be on better footing than it was earlier in the year, when the trade situation looked more dire and consumer sentiment was declining. But JPMorgan Chase CEO Jamie Dimon remains cautious, adopting a view that goes against that of other bank executives, who are more optimistic. "Significant risks persist -- including from tariffs and trade uncertainty, worsening geopolitical conditions, high fiscal deficits and elevated asset prices," Dimon said in a press release. His commentary points to an issue that investors might have, which is that banks generally are cyclical companies. Their performance is tied to macro forces, particularly the trajectory of interest rates. The challenge is that it's impossible to predict what direction interest rates are going in, although many believe the Federal Reserve will cut them later this year, a move that could spur lending activity and boost confidence among consumers and corporate executives. At this point, JPMorgan Chase deserves the benefit of the doubt in that it should be able to navigate any economic turmoil that comes its way. It has a robust capital position, for instance. JPMorgan Chase is considered a global systemically important bank by the Financial Stability Board. Its size and scope make it critical to the functioning of our economy, so the government likely won't let it fail in an adverse situation because of the bigger problems that could cause. From an investment perspective, this can help give shareholders peace of mind knowing that the bank's downside is supported. High quality, high expectations Most investors would consider JPMorgan Chase the top banking entity in the industry, thanks to its impressive financial performance and the capability of its CEO. The stock's 252% five-year total return reflects just how much the market appreciates this company. However, it's time to take a closer look at the valuation. To be clear, shares do not look cheap by any measure. The current price-to-earnings ratio is 15.3, the highest it's been in three years. The price-to-book ratio, which is a valuation tool that's more pertinent in the banking industry, is above 2.4. This is the most expensive reading of this metric in 20 years. It's safe to say that JPMorgan Chase stock is trading far from bargain territory. While I believe that this is a high-quality company, the best thing investors can do is to wait for a more attractive valuation before buying shares. Should you invest $1,000 in JPMorgan Chase right now? Before you buy stock in JPMorgan Chase, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and JPMorgan Chase wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy. Is JPMorgan Chase Stock a Buy Right Now? was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
an hour ago
- Business Insider
A 'seismic' 39% tariff on Switzerland is rocking the watch world, and even pre-owned Rolexes could see price hikes
Watch collectors might want to skip the Rolex boutique and head straight for the pawn shop this year. That is, if the Trump administration's new 39% tariff on goods from Switzerland sticks. The White House released updated tariff plans on Thursday, raising the rate from the proposed 31% announced earlier this year. The tariff escalation caught the watch community off guard. Switzerland is a manufacturing hub for luxury watches like Rolex and Cartier. Eugene Tutunikov, CEO of watch marketplace Swiss Watch Expo, told Business Insider the announcement "was a complete shock" and that "its effects will be immediate." Leading brands, including Rolex, have already raised prices in the US this year, likely in response to tariffs, Morgan Stanley analysts wrote in a July report about the Swiss watch market. US imports of Swiss goods have faced a 10% baseline tariff since April. A new 39% tariff on Swiss imports to the US would put more pressure on luxury watchmakers. That could lead to higher prices on Swiss-made goods shipped to the US, or less inventory for American shoppers. While the Swiss government could still try to negotiate, the tariff is currently set to take effect on August 7. Collectors and watchmakers may soon have to reckon with this new reality. Joshua Ganjei, CEO of watch marketplace European Watch Company, thinks more shoppers will turn to pre-owned models of high-end watches like Rolexes over brand-new ones. After all, a secondhand watch from a US-based seller won't face the added cost of a new Swiss-made model shipped from overseas. "For many American collectors, the 39% tariff instantly turned new releases from Swiss brands into a luxury few can justify," Ganjei said. According to the Morgan Stanley report, pre-owned watch dealers have reported an increase in demand this year since Swiss-made brands began raising their prices in the US. Prices in the secondhand market have been falling since mid-2022, though the rate of decline has narrowed. Pre-owned watches could also get more expensive, though. While the inventory already in the US won't face tariffs, heightened demand could drive up prices on the secondary market as well. Tutunikov said he thinks the pre-owned market will react to higher tariffs "much faster" than large retailers and hike prices sooner. He expects prices on the secondary market to jump as much as 10% in the next month and potentially reach up to 35% in the next six months, "as demand overwhelmingly shifts to available inventory." "This isn't just a tax; it's a seismic event that will cause a stark divergence between the new and pre-owned markets," Tutunikov said.
Yahoo
an hour ago
- Yahoo
Why AbbVie Stock Flew Higher on Friday
Key Points A trio of analysts raised their price targets on the pharmaceutical sector mainstay. This came a day after it published second-quarter results. 10 stocks we like better than AbbVie › A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (NYSE: ABBV) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in no small part to a clutch of post-earnings analyst price-target increases. With that performance, Abbvie crushed the S&P 500 index, which dived by 1.6% on the day. A bullish stampede As typically happens when a publicly traded company posts better-than-expected quarterly results, those pundits made the positive changes a day after AbbVie published its estimates-besting second-quarter figures. None of the price-target hikes were particularly dramatic, but since they came from analysts already bullish on AbbVie, they boosted sentiment on the stock. Morgan Stanley's Terrance Flynn now feels the shares are worth $255 apiece, up from his previous level of $250. His peers Gary Nachman at Raymond James and Guggenheim's Vamil Divan also upped their fair value assessments. In the former's case, he added $9 per share for a new price target of $236, while the latter increased his to $227 from $216. All three analysts maintained their equivalent of a buy recommendation on the stock. Blockbuster success Divan's note detailing his price-target change indicated the general tone of those modifications. According to reports, the pundit expressed admiration for the company's performance, singling out the growth in sales of certain blockbuster drugs, notably Skyrizi. Divan pointed out that much of this improvement was due to volume growth, meaning demand remains strong for such products. Should you buy stock in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy. Why AbbVie Stock Flew Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
